Bayer AG

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Shares in seeds and pesticides maker Bayer  opened 2.3% higher on Friday, driven by a report on a possible out-of-court settlement of a U.S. jury trial over allegations that its weed killer Roundup causes cancer.

Bayer Shares up 2.3% on report about possible glyphosate settlement

Bayer AG  is set to face a fourth U.S. jury trial over allegations that its popular weed killer Roundup causes cancer, with four cancer patients in the hometown of its agricultural subsidiary Monsanto scheduled to make their case beginning on Friday.

Bayer faces fourth U.S. Roundup cancer trial in Monsanto home court

Despite getting approval in the U.S. and Canada, European counterparts weren't impressed by Vitraki.

Bayer's Cancer Drug Vitraki Rejected by Both England and Germany

Bayer  could be close to settling more than 75,000 cancer claims related to its Roundup herbicide, with mediator Ken Feinberg on Friday saying he was "cautiously optimistic that a settlement will ultimately be reached."

Bayer could be close to Roundup settlement, mediator says

Bayer  is close to settling more than 75,000 cancer claims related to its Roundup herbicide, mediator Ken Feinberg told Bloomberg in an interview, saying he was "cautiously optimistic" a deal could be reached in about a month.

Bayer close to Roundup settlement, mediator tells Bloomberg

Bayer: The Spectre Of Monsanto Conceals The Bargain Here

Bayer  shares rose as much as 3.5% on Monday, reaching their highest level in 14 months, after the United States government said that a $25 million glyphosate decision against the company should be reversed.

Bayer shares up 3.5% after U.S. government's backing in glyphosate lawsuit

The U.S. Environmental Protection Agency and the Justice Department said a federal appeals court should reverse a lower court verdict finding Bayer AG liable in the case of a California man who blamed its Roundup weed killer for his cancer.

U.S. government says verdict in Bayer's Roundup case should be reversed

Bayer AG  on Monday said it has asked a U.S. federal appeals court to throw out a $25 million judgment it was ordered to pay to a California man who blamed the company's Roundup weed killer for his cancer.

Bayer asks U.S. appeals court to reverse $25 million Roundup verdict

Adding Bayer To My Repurchase List

Germany's Bayer  has agreed with plaintiffs to postpone its next two U.S. lawsuits over the alleged cancer-causing effects of its glyphosate-based weed killers to allow more time for talks on a settlement.

Bayer reaches agreement to postpone more glyphosate lawsuits for settlement talks

Teva Pharmaceutical

In a late October article, Bayer (XTER:BAYN) was credited with making one of the worst corporate deals ever with its acquisition of Monsanto.

Bayer and Teva Double Down on Worst M&A Deals of Decade

Monsanto pleaded guilty to spraying a banned pesticide on the Hawaiian island of Maui, and agreed to pay $10.2 million in criminal fines and other payments for the spraying and for illegally storing hazardous waste, U.S. prosecutors said.

Bayer's Monsanto pleads guilty to illegal Hawaii pesticide spraying

Mediation between Bayer and plaintiffs in the United States aims to clarify all justified claims related to Roundup herbicide both at the national and state level, mediator Ken Feinberg told a German magazine.

Mediation between Bayer, plaintiffs seeks to clarify all justified claims: U.S. mediator

Bayer Aktiengesellschaft (BAYZF) CEO Werner Baumann on Q3 2019 Results - Earnings Call Transcript

Bayer's (BAYRY) earnings beat and revenues rise on the back of growth across all reported segments in the third quarter. The company updates guidance to include impact of discontinued operations.

Bayer (BAYRY) Q3 Earnings Beat Estimates, Sales Rise Y/Y

Bayer , the world's largest maker of seeds and pesticides, said U.S. farmers were unperturbed by lawsuits seeking damages from Bayer for an alleged cancer-causing effect of glyphosate-based herbicides.

Bayer says U.S. farmers unfazed by glyphosate litigation

Bayer faces a surge in lawsuits from people alleging that its weedkiller Roundup causes cancer, ratcheting up legal pressure company engages in settlement. 
The post Bayer Is Now Facing 42,700 Plaintiffs In Roundup Litigation appeared first on Investor's Business Daily.

Bayer Is Now Facing 42,700 Plaintiffs In Roundup Litigation

Germany's Bayer  said on Wednesday that the number of U.S. plaintiffs blaming its glyphosate-based weedkillers for their cancer mushroomed to 42,700 from 18,400 in July, raising the stakes in the group's efforts to reach a settlement.

Bayer says number of glyphosate plaintiffs jumps to 42,700

The lesson here is that smaller acquisitions may have a better chance of benefiting investors.

And the Winner for the Worst Corporate Deal is Bayer

Two Seattle-area startups were hand-picked by Bayer for a competitive program to create novel digital health solutions.

Bayer partners with Seattle startups Litesprite and Prevencio on digital health efforts

Bayer  expects the number of claims in the United States related to Roundup herbicide to have surged in the third quarter, as the German drugs and pesticides maker tries to reach a settlement after earlier court rulings against it.

Bayer expects significant surge in number of U.S. glyphosate cases

An Australian farmer has launched a legal action against Bayer AG’s agricultural chemicals unit Monsanto after being diagnosed with a type of cancer he claims was caused by its weedkiller, the Australian Broadcasting Commission reported on Thursday.

Australian farmer brings legal action vs Bayer over weedkiller: report

(This October 6 story has been refilled to correct "until February" to "until further notice" in headline and "new court date" to "court status conference" in paragraphs 1 & 6)

Bayer says Oct. U.S. glyphosate trial delayed until further notice

A pending U.S. lawsuit over claims related to Bayer's  glyphosate-based herbicide Roundup has been delayed, the company said on Sunday.

News for Bayer AG Stock (BAYRY)